Rise of personalized drugs means fewer 'dinosaur' trials

Now that targeted therapies like Roche's ($RHHBY) Zelboraf and Bayer's Stivarga have raced through the FDA and into patients' hands, drug developers are relying less and less on old-fashioned randomized controlled trials. As researchers told Reuters, if you're testing a drug you know only affects patients with, say, certain VEGF mutations, why waste time with "dinosaur" trials involving people who almost surely won't benefit? The FDA is so far all aboard with the single-arm revolution, fast-tracking personalized drugs left and right. However, as drugmakers chart quicker--and thus cheaper--paths through development, the market has yet to see a mirrored effect on drug pricing. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.